V

Viridian Therapeutics
D

VRDN

16.250
USD
-0.35
(-2.11%)
مغلق
حجم التداول
27,883
الربح لكل سهم
-4
العائد الربحي
-
P/E
-4
حجم السوق
1,287,207,139
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
الأخبار
المقالات

العنوان: Viridian Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.